{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:12Z","timestamp":1786979892188,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Severe ADAMTS13 deficiency (activity &amp;lt;10%) is the diagnostic threshold for thrombotic thrombocytopenic purpura (TTP) and is associated with various clinical symptoms, abnormal laboratory results, and long-term complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective, noninterventional cohort study used the Premier Healthcare Database to identify patients with ADAMTS13 activity of &amp;lt;10% in US hospitals from January 1, 2016, through March 31, 2020. The objective was to describe patient characteristics, laboratory results, comorbidities (as measured by the Elixhauser comorbidity index), symptoms, length of stay, treatment patterns, mortality, inpatient costs, and readmission rates (summarized descriptively). Inpatient costs were calculated as total cost to the hospital.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 211 patients with severe ADAMTS13 deficiency; 89% of patients had a TTP-related diagnosis, of whom 62% had a primary diagnosis of thrombotic microangiopathy. Over 80% of patients with available data had a decreased platelet count and elevated lactate dehydrogenase; schistocytes were detected in 99%. The most prevalent symptoms\/complications were neurological, bleeding, and pain. Most patients (86%) had 2 or more Elixhauser comorbidities. Over 80% of patients received 1 or more TTP-related treatments, mostly plasma exchange. The mean length of stay was 11.5 days; 5% of patients died during their stay. Readmission rates at 30, 60, and 90 days were 20%, 26%, and 28%, respectively. The median (interquartile range) total inpatient cost to the hospital throughout the index admission was $33,221 ($19,431-$64,901).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients with severe ADAMTS13 deficiency have substantial clinical burden, have high mortality and readmission rates, and generate high costs for hospitals. There is a high need for a therapy that replaces ADAMTS13, thus addressing the root cause of the symptoms and complications caused by this deficiency.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae167","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T19:20:04Z","timestamp":1720725604000},"page":"1278-1287","source":"Crossref","is-referenced-by-count":5,"title":["Clinical and economic burden of suspected thrombotic thrombocytopenic purpura in US hospitals"],"prefix":"10.1093","volume":"81","author":[{"given":"Shan","family":"Xing","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc. , Lexington, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bullano","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc. , Lexington, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hale","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc. , Lexington, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Lokhandwala","sequence":"additional","affiliation":[{"name":"Xcenda LLC , Carrollton, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharanya","family":"Murty","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"21","key":"2024121018582563800_CIT0001","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024121018582563800_CIT0002","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2024121018582563800_CIT0003","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0039-1679907","article-title":"Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: fourteen years of the Milan TTP Registry","volume":"119","author":"Mancini","year":"2019","journal-title":"Thromb Haemost"},{"issue":"4","key":"2024121018582563800_CIT0004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2141.2004.05217.x","article-title":"von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Peyvandi","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"2024121018582563800_CIT0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030536","article-title":"Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management","volume":"10","author":"Sukumar","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"2024121018582563800_CIT0006","doi-asserted-by":"crossref","first-page":"e0179258","DOI":"10.1371\/journal.pone.0179258","article-title":"Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease","volume":"12","author":"Denorme","year":"2017","journal-title":"PLoS One"},{"issue":"25","key":"2024121018582563800_CIT0007","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","article-title":"Low ADAMTS13 activity is associated with an increased risk of ischemic stroke","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2024121018582563800_CIT0008","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2024121018582563800_CIT0009","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/jth.13016","article-title":"Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity: reply","volume":"13","author":"Zafrani","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2024121018582563800_CIT0010","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"2024121018582563800_CIT0011","author":"Premier Applied Sciences"},{"issue":"4","key":"2024121018582563800_CIT0012","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2024121018582563800_CIT0013","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"issue":"10","key":"2024121018582563800_CIT0014","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"van Dorland","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"2024121018582563800_CIT0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.25122\/jml-2021-0361","article-title":"The economic burden of stroke: a systematic review of cost of illness studies","volume":"14","author":"Strilciuc","year":"2021","journal-title":"J Med Life"},{"issue":"11","key":"2024121018582563800_CIT0016","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1161\/STROKEAHA.110.610881","article-title":"In-hospital medical complications, length of stay, and mortality among stroke unit patients","volume":"42","author":"Ingeman","year":"2011","journal-title":"Stroke"},{"issue":"9","key":"2024121018582563800_CIT0017","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00277-015-2411-2","article-title":"Headache prevalence following recovery from TTP and aHUS","volume":"94","author":"Saultz","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"2024121018582563800_CIT0018","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: long-term outcomes following recovery","volume":"2018","author":"George","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2024121018582563800_CIT0019","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/16078454.2021.1945236","article-title":"Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) - cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom","volume":"26","author":"Holmes","year":"2021","journal-title":"Hematology"},{"issue":"6","key":"2024121018582563800_CIT0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"2024121018582563800_CIT0021","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1111\/jth.13479","article-title":"Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study","volume":"14","author":"Sonneveld","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2024121018582563800_CIT0022","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/bloodadvances.2020004169","article-title":"Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission","volume":"6","author":"Sukumar","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2024121018582563800_CIT0023","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.amjmed.2020.06.020","article-title":"Cardiovascular complications and their association with mortality in patients with thrombotic thrombocytopenic purpura","volume":"134","author":"Balasubramaniyam","year":"2021","journal-title":"Am J Med"},{"issue":"3","key":"2024121018582563800_CIT0024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2024121018582563800_CIT0025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/jcm11041103","article-title":"Severe thrombotic thrombocytopenic purpura (TTP) with organ failure in critically ill patients","volume":"11","author":"Fodil","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"2024121018582563800_CIT0026","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/13696998.2021.1922262","article-title":"Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura","volume":"24","author":"Pollissard","year":"2021","journal-title":"J Med Econ"},{"issue":"7","key":"2024121018582563800_CIT0027","doi-asserted-by":"crossref","first-page":"509","DOI":"10.14740\/jocmr3850","article-title":"Connective tissue disorders in patients with thrombotic thrombocytopenic purpura: a retrospective analysis using a national database","volume":"11","author":"Sharma","year":"2019","journal-title":"J Clin Med Res"},{"issue":"10","key":"2024121018582563800_CIT0028","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.1002\/ajh.24138","article-title":"Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura","volume":"90","author":"Chaturvedi","year":"2015","journal-title":"Am J Hematol"},{"issue":"7","key":"2024121018582563800_CIT0029","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.2020009250","article-title":"Counting the cost of caplacizumab","volume":"137","author":"Chaturvedi","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2024121018582563800_CIT0030","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024121018582563800_CIT0031","doi-asserted-by":"crossref","first-page":"546","DOI":"10.5858\/arpa.2013-0170-OA","article-title":"Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura","volume":"138","author":"Barrows","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"2024121018582563800_CIT0032","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/j.1537-2995.2012.03646.x","article-title":"Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011","volume":"52","author":"Som","year":"2012","journal-title":"Transfusion"},{"issue":"4","key":"2024121018582563800_CIT0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2024121018582563800_CIT0034","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2024121018582563800_CIT0035","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2024121018582563800_CIT0036","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024121018582563800_CIT0037","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.17560","article-title":"Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort","volume":"194","author":"Sakai","year":"2021","journal-title":"Br J Haematol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae167\/58776969\/zxae167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/24\/1278\/60956186\/zxae167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/24\/1278\/60956186\/zxae167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:57:23Z","timestamp":1733860643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/24\/1278\/7712378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":37,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,7,11]]},"published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae167","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,15]]},"published":{"date-parts":[[2024,7,11]]}}}